| Literature DB >> 29354092 |
Susanna Mezzarobba1,2,3, Michele Grassi1, Lorella Pellegrini2,3, Mauro Catalan2, Bjorn Kruger4, Giovanni Furlanis2, Paolo Manganotti2,3, Paolo Bernardis1.
Abstract
Freezing of gait (FoG) is a disabling symptom associated with falls, with little or no responsiveness to pharmacological treatment. Current protocols used for rehabilitation are based on the use of external sensory cues. However, cued strategies might generate an important dependence on the environment. Teaching motor strategies without cues [i.e., action observation (AO) plus Sonification] could represent an alternative/innovative approach to rehabilitation that matters most on appropriate allocation of attention and lightening cognitive load. We aimed to test the effects of a novel experimental protocol to treat patients with Parkinson's disease (PD) and FoG, using functional, and clinical scales. The experimental protocol was based on AO plus Sonification. 12 patients were treated with 8 motor gestures. They watched eight videos showing an actor performing the same eight gestures, and then tried to repeat each gesture. Each video was composed by images and sounds of the gestures. By means of the Sonification technique, the sounds of gestures were obtained by transforming kinematic data (velocity) recorded during gesture execution, into pitch variations. The same 8 motor gestures were also used in a second group of 10 patients; which were treated with a standard protocol based on a common sensory stimulation method. All patients were tested with functional and clinical scales before, after, at 1 month, and 3 months after the treatment. Data showed that the experimental protocol have positive effects on functional and clinical tests. In comparison with the baseline evaluations, significant performance improvements were seen in the NFOG questionnaire, and the UPDRS (parts II and III). Importantly, all these improvements were consistently observed at the end, 1 month, and 3 months after treatment. No improvement effects were found in the group of patients treated with the standard protocol. These data suggest that a multisensory approach based on AO plus Sonification, with the two stimuli semantically related, could help PD patients with FoG to relearn gait movements, to reduce freezing episodes, and that these effects could be prolonged over time.Entities:
Keywords: Parkinson’s disease; Sonification; action observation; cueing; freezing of gait
Year: 2018 PMID: 29354092 PMCID: PMC5758544 DOI: 10.3389/fneur.2017.00723
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Flowchart showing the structure of the study, enrollment and evaluation procedure, and how the patients were divided into the groups, and phases.
Demographic and clinical characteristics of patients with Parkinson’s disease at baseline.
| AOS group ( | Cue group ( | |
|---|---|---|
| Gender female/male (% female) | 5/7 (42%) | 3/7 (30%) |
| Age (years) | 74.67 ± 5.93 | 72 ± 5.87 |
| Disease duration (years) | 10.75 ± 3.44 | 9.4 ± 4.86 |
| Mini-Mental State Exam | 27.46 ± 1.81 | 26.58 ± 1.1 |
| Beck Depression Inventory | 8 ± 5.98 | 6.4 ± 5.93 |
| Hoehn and Yahr stage | 2.33 ± 0.49 | 2.3 ± 0.67 |
| Levodopa equivalent | 972.5 ± 253.17 | 983.22 ± 379.58 |
| NFOGQ | 18.17 ± 4.61 | 16.6 ± 7.86 |
| UPDRS II Total | 16.42 ± 5.99 | 17.1 ± 6.47 |
| UPDRS III Total | 32.92 ± 8.69 | 33.2 ± 13.99 |
| MPAS | 53.75 ± 6.27 | 50.2 ± 9.22 |
| BBS | 47.75 ± 4.16 | 47.8 ± 3.46 |
| 6MWT (s) | 280.75 ± 93.34 | 296.75 ± 48.32 |
| TUG (ms) | 1,299.75 ± 376.74 | 1,271.3 ± 615.86 |
| PDQ39 mobility | 49.38 ± 22.54 | 35.5 ± 25.87 |
| PDQ39 activities of daily living | 33.4 ± 21.99 | 28.75 ± 17.84 |
| PDQ39 emotional well-being | 23.82 ± 21.84 | 33.33 ± 20.13 |
| PDQ39 stigma | 21.04 ± 22.94 | 18.75 ± 20.41 |
| PDQ39 social support | 2.78 ± 6.49 | 15.83 ± 22.03 |
| PDQ39 cognitions | 23.23 ± 15.52 | 31.88 ± 19.64 |
| PDQ39 communication | 24.31 ± 20.86 | 29.17 ± 21.25 |
| PDQ39 bodily discomfort | 31.67 ± 21.92 | 27.5 ± 19.27 |
| PDQ39 Total | 51.67 ± 26.9 | 50.8 ± 29.43 |
Data are mean ± SD or as otherwise indicated.
n, number of patients; NFOGQ, New Freezing of Gait Questionnaire; UPDRS, Unified Parkinson’s Disease Rating Scale II and III; PDQ39, Parkinson’s disease questionnaire 39; MPAS, Modified Parkinson’s Activity Scale; BBS, Berg Balance Scale; 6MWT, 6-min walking test; TUG, Time-Up-and-Go; PDQ39, 39-item PD Questionnaire.
Cognitive profile of patients with Parkinson’s disease at baseline and at 1-month follow-up (1MFU).
| Cognitive domain | Test | AOS group at baseline | Cue group at baseline | AOS group at 1MFU | Cue group at 1MFU |
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | ||
| Short-term memory | Digit Span Backward | 4.84 ± 1.27 | 4.84 ± 1.14 | 4.59 ± 1.14 | 4.58 ± 1.02 |
| Corsi Test | 4.85 ± 0.84 | 4.34 ± 0.84 | 4.50 ± 0.83 | 5.01 ± 1.44 | |
| Long-term memory | Babcock Story Recall Test | ||||
| Immediate recall | 5.78 ± 1.51 | 4.52 ± 2.48 | 5.27 ± 1.62 | 3.83 ± 2.50 | |
| Delayed recall | 5.8 ± 1.4 | 4.41 ± 3.07 | 5.16 ± 1.88 | 3.41 ± 3.27 | |
| Attention | Attentive Matrices | 40.94 ± 8.35 | 32.46 ± 12.86 | 36.91 ± 11.27 | 31.56 ± 13.51 |
| Trail Making Test: | |||||
| Part A (s) | 30.35 ± 21.59 | 68.51 ± 46.78 | 52.44 ± 45.98 | 55.27 ± 38.02 | |
| Part B (s) | 147.34 ± 116.51 | 190.58 ± 130.99 | 148.35 ± 199.33 | 166.68 ± 117.38 | |
| Stroop Test | |||||
| Time (s) | 28.78 ± 19.19 | 52.73 ± 42.05 | 42.59 ± 26.17 | 47.72 ± 29.42 | |
| Errors | 3.01 ± 3.55 | 1.83 ± 1.76 | 3.64 ± 2.47 | 3.36 ± 3.39 | |
| Executive functions | Frontal Assessment Battery | 16.7 ± 1.22 | 16.19 ± 1.71 | 16.55 ± 1.78 | 16.11 ± 1.80 |
| Tower of London Test | 17.99 ± 1.4 | 19.56 ± 6.38 | 18.61 ± 0.29 | 18.22 ± 1.41 | |
| Reasoning | Raven’s progressive matrices | 29.71 ± 6.18 | 27.28 ± 5.17 | 28.85 ± 6.16 | 27.70 ± 5.31 |
Data are mean ± SD or as otherwise indicated.
Split plot ANOVA results.
| SS | Mean sq | F | Pr(>F) | η2G (%) | |
|---|---|---|---|---|---|
| NFOGQ | 2.741 | 2.741 | 24.28 | 0.000 | 50 |
| PDQ39 mobility | 12.630 | 12.633 | 14.91 | 0.001 | 38 |
| UPDRSIII | 4.962 | 4.962 | 13.36 | 0.002 | 33 |
| PDQ39 bodily discomfort | 4.962 | 4.962 | 13.36 | 0.002 | 33 |
| PDQ39 Total | 2.031 | 2.031 | 9.73 | 0.006 | 27 |
| UPDRSII | 1.427 | 1.427 | 11.14 | 0.003 | 24 |
| BBS | 0.121 | 0.121 | 6.42 | 0.020 | 24 |
| 6MWT | 0.470 | 0.470 | 4.11 | ns | 15 |
| TUG | 1.070 | 1.071 | 3.95 | ns | 14 |
| MPAS | 0.021 | 0.021 | 0.56 | ns | 2 |
| PDQ39 cognitions | 0.471 | 0.471 | 0.47 | ns | 2 |
| NFOGQ | 0.091 | 0.046 | 3.11 | ns | 3 |
| PDQ39 mobility | 0.151 | 0.075 | 0.60 | ns | 1 |
| UPDRSIII | 0.334 | 0.167 | 2.14 | ns | 3 |
| PDQ39 bodily discomfort | 0.334 | 0.167 | 2.14 | ns | 3 |
| PDQ39 Total | 0.158 | 0.079 | 2.05 | ns | 3 |
| UPDRSII | 0.049 | 0.025 | 0.48 | ns | 1 |
| BBS | 0.005 | 0.003 | 3.01 | ns | 1 |
| 6MWT | 0.061 | 0.031 | 2.91 | ns | 2 |
| TUG | 0.222 | 0.111 | 3.66 | 0.035 | 3 |
| MPAS | 0.009 | 0.005 | 0.69 | ns | 1 |
| PDQ39 cognitions | 1.546 | 0.773 | 4.17 | 0.023 | 6 |
| NFOGQ | 0.002 | 0.001 | 0.07 | ns | 0 |
| PDQ39 mobility | 0.386 | 0.193 | 1.54 | ns | 2 |
| UPDRSIII | 0.197 | 0.098 | 1.26 | ns | 2 |
| PDQ39 bodily discomfort | 0.197 | 0.098 | 1.26 | ns | 2 |
| PDQ39 Total | 0.261 | 0.131 | 3.41 | 0.043 | 5 |
| UPDRSII | 0.047 | 0.023 | 0.46 | ns | 1 |
| BBS | 0.002 | 0.001 | 0.90 | ns | 0 |
| 6MWT | 0.022 | 0.011 | 1.03 | ns | 1 |
| TUG | 0.034 | 0.017 | 0.56 | ns | 1 |
| MPAS | 0.014 | 0.007 | 1.02 | ns | 1 |
| PDQ39 cognitions | 0.451 | 0.225 | 1.22 | ns | 2 |
ns, not significant; NFOGQ, New Freezing of Gait Questionnaire; UPDRS, Unified Parkinson’s Disease Rating Scale II and III; PDQ39: Parkinson’s disease questionnaire 39; MPAS, Modified Parkinson’s Activity Scale; BBS, Berg Balance Scale; 6MWT, 6-min walking test; TUG, Time-Up-and-Go; PDQ39, 39-item PD Questionnaire; SS, sum of squares.
UPDRSIII, TUG, PDQ39 mobility, and PDQ39 bodily discomfort were log transformed for normality. Index η.
Figure 2Improvement (gain) of the two groups in the primary outcome measure [New Freezing of Gait Questionnaire (NFOGQ)], at the three evaluation times. Error bars are 1 SE.
Figure 3Improvement (gain) of the two groups in five secondary outcome measures [Unified Parkinson’s Disease Rating Scale: parts II and III (UPDRS) and Parkinson’s disease questionnaire 39 (PDQ39): mobility, bodily discomfort, and the total score], at the three evaluation times. Error bars are 1 SE.
Bonferroni post hoc comparisons AOS group vs. cue group.
| After treatment | 1st Follow-up | 2nd Follow-up | |
|---|---|---|---|
| NFOGQ | |||
| PDQ39 mobility | |||
| UPDRSIII | |||
| PDQ39 bodily discomfort | |||
| PDQ39 Total | ns | ||
| UPDRSII | ns | ||
| BBS | ns | ns | |
| 6MWT | ns | ns | |
| TUG | ns | ns | ns |
| MPAS | ns | ns | ns |
| PDQ39 cognitions | ns | ns | ns |
Data are p-levels of the direct comparisons at each evaluation time, between groups, after the Bonferroni correction.
NFOGQ, New Freezing of Gait Questionnaire; UPDRS, Unified Parkinson’s Disease Rating Scale II and III; PDQ39, Parkinson’s disease questionnaire 39; MPAS, Modified Parkinson’s Activity Scale; BBS, Berg Balance Scale; 6MWT, 6-min walking test; TUG, Time-Up-and-Go; ns, not significant.
Figure 4Average discrimination accuracy expressed in terms of sensitivity (d′) of the linear discriminant analysis (LDA) algorithm. (A) Results of testing between-groups’ discrimination. Dark gray bars represent LDA results from the New Freezing of Gait Questionnaire (NFOGQ) and UPDRS III scales. Light gray bars represent LDA results from the PDQ39 mobility and bodily discomfort scales. (B) Results of testing within-subject discrimination. Dark and light red bars represent LDA results from the NFOGQ and UPDRS III scales for the Action Observation plus Sonification experimental group. Dark and light blue bars represent LDA results from the PDQ39 mobility and bodily discomfort scales, for the Cue control group.